Cullinan Oncology Announces Management Transition
May 21, 2021 08:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today...
Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021
May 19, 2021 17:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today...
Cullinan Oncology Reports First Quarter 2021 Financial Results
May 14, 2021 06:30 ET
|
Cullinan Oncology, Inc.
Continued advancement of broad portfolio, highlighted by initiation of Phase 2a dose expansion of Cullinan Pearl in NSCLC patients with EGFRex20ins mutations Cash, cash equivalents and investments of...
Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 07, 2021 10:08 ET
|
Cullinan Management, Inc.
CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that the company’s Chief Financial Officer, Jeff Trigilio, will present at...
Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights
March 30, 2021 06:15 ET
|
Cullinan Management, Inc.
Pipeline Progress: Clinical and preclinical programs continue to advance, with encouraging initial Cullinan Pearl data and additional INDs to be filed in 2021 for immuno-oncology assets Cullinan...
Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference
March 02, 2021 09:48 ET
|
Cullinan Management, Inc.
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted...
Cullinan Management, Inc. Announces Business Update
February 22, 2021 07:30 ET
|
Cullinan Management, Inc.
February 22, 2021 Enrollment expansion in CLN-081 NSCLC EGFRex20ins Phase 1/2a trialCullinan withdraws IND application for CLN-049 in Relapsed/Refractory AMLCLN-619 IND submission planned for the...
Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 12, 2021 21:43 ET
|
Cullinan Management, Inc.
CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and...
Cullinan Management Announces Pricing of Upsized Initial Public Offering (CORRECTION)
January 08, 2021 00:13 ET
|
Cullinan Management, Inc.
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Please note that the embedded hyperlinks in the press release below have been corrected from a release issued under the same headline earlier...
Cullinan Management Announces Pricing of Upsized Initial Public Offering
January 07, 2021 21:03 ET
|
Cullinan Management, Inc.
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc., a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology...